Vulvovaginal Candidiasis and Bacterial Vaginosis

Infectious Disease Clinics of North America

Volumn 22, Issue 4, 2008, Pages 637-652

  Nyirjesy, Paul ^a  

^a UNIVERSITY OF NORTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; BORIC ACID; BUTOCONAZOLE; CLINDAMYCIN; CLOTRIMAZOLE; CORTICOSTEROID; FLUCONAZOLE; FLUCYTOSINE; KETOCONAZOLE; LITHIUM; MEDROXYPROGESTERONE; METRONIDAZOLE; MICONAZOLE; NON PRESCRIPTION DRUG; NYSTATIN; ORAL CONTRACEPTIVE AGENT; PLACEBO; SPERMICIDAL AGENT; TINIDAZOLE; TIOCONAZOLE; WARFARIN;

ANOREXIA; BACTERIAL COLONIZATION; CANDIDA; CANDIDA GLABRATA; CANDIDA TROPICALIS; CANDIDIASIS; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; GARDNERELLA VAGINALIS; GASTROINTESTINAL INTOLERANCE; GASTROINTESTINAL IRRITATION; GYNECOLOGICAL EXAMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; INFECTION RISK; LIVER TOXICITY; LOW BIRTH WEIGHT; MIXED INFECTION; MONOTHERAPY; NAUSEA; NEWBORN INFECTION; PRESCRIPTION; RASH; RECURRENT DISEASE; REPEATED DRUG DOSE; REVIEW; SEXUAL TRANSMISSION; SEXUALITY; SIDE EFFECT; SINGLE DRUG DOSE; SKIN IRRITATION; SYMPTOM; TERATOGENESIS; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINA FLORA; VAGINITIS; WOMEN'S HEALTH;

ADULT; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CANDIDIASIS, VULVOVAGINAL; FEMALE; HUMANS; VAGINOSIS, BACTERIAL;

EID: 54049108162     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2008.05.002     Document Type: Review

References (82)

1. Lipsky M.S., Waters T., and Sharp L.K. Impact of vaginal antifungal products on utilization of health care services: evidence from physician visits. J Am Board Fam Pract 13 (2000) 178-182
2. Anderson M.R., Klink K., and Cohrssen A. Evaluation of vaginal complaints. JAMA 291 (2004) 1368-1379
3. Marrazzo J.M. Vulvovaginal candidiasis. BMJ 326 (2003) 993-994
4. Foxman B., Barlow R., D'Arcy H., et al. Candida vaginitis: self-reported incidence and associated costs. Sex Transm Dis 27 (2000) 230-235
5. Ferris D.G., Dekle C., and Litaker M.S. Women's use of over-the-counter antifungal medications for gynecological symptoms. J Fam Pract 42 (1996) 595-600
6. Ferris D.G., Nyirjesy P., Sobel J.D., et al. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol 99 (2002) 419-425
7. Allen-Davis J.T., Beck A., Parker R., et al. Assessment of vulvovaginal complaints: accuracy of telephone triage and in-office diagnosis. Obstet Gynecol 99 (2002) 18-22
8. Wiesenfeld H.C., and Macio I. The infrequent use of office-based diagnostic tests for vaginitis. Am J Obstet Gynecol 181 (1999) 39-41
9. Ledger W.J., Polaneczky M.M., Yih M.C., et al. Difficulties in the diagnosis of Candida vaginitis. Infectious Diseases in Clinical Practice 9 (2000) 66-69
10. Nyirjesy P., Peyton C., Weitz M.V., et al. Causes of chronic vaginitis: analysis of a prospective database of affected women. Obstet Gynecol 108 (2006) 1185-1191
11. Sobel J.D., Faro S., Force R.W., et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 178 (1998) 203-211
12. Beigi R.H., Meyn L.A., Moore D.M., et al. Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet Gynecol. 104 (2004) 926-930
13. Centers for Disease Control and Prevention, Workowski K.A., and Berman S.M. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 55 RR-11 (2006) 51-56
14. Sobel J.D., Kapernick P.S., Zervos M., et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 185 (2001) 363-369
15. Nyirjesy P., Seeney S.M., Grody M.H.T., et al. Chronic fungal vaginitis: The value of cultures. Am J Obstet Gynecol 173 (1995) 820-823
16. Sobel J.D., Wiesenfeld H.C., Martens M., et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 351 9 (2004) 876-883
17. Trama J.P., Adelson M.E., Raphaelli I., et al. Detection of Candida species in vaginal samples in a clinical laboratory setting. Infect Dis Obstet Gynecol 13 2 (2005) 63-67
18. Singh S., Sobel J.D., Bhargava P., et al. Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. Clin Infect Dis 35 9 (2002) 1066-1070
19. Richter S.S., Galask R.P., Messer S.A., et al. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 43 5 (2005) 2155-2162
20. Hillier S.L., and Lau R.J. Vaginal microflora in postmenopausal women who have not received estrogen replacement therapy. Clin Infect Dis 25 Suppl 2 (1997) S123-S126
21. Vazquez J.A., Sobel J.D., Demitriou R., et al. Karyotyping of Candida albicans isolates obtained longitudinally in women with recurrent vulvovaginal candidiasis. J Infect Dis 170 (1994) 1566-1569
22. Geiger A.M., and Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology 7 (1996) 182-187
23. DeLeon E.M., Jacober S.J., Sobel J.D., et al. Prevalence and risk factors for vaginal Candida colonization in women with type I and type II diabetes. BMC Infect Dis 2 (2002) 1-11
24. Donders G.G., Prenen H., Verbeke G., et al. Impaired tolerance for glucose in women with recurrent vaginal candidiasis. Am J Obstet Gynecol 187 (2002) 989-993
25. Spinillo A., Capuzzo E., Acciano S., et al. Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis. Am J Obstet Gynecol 180 (1999) 14-17
26. Pirotta M.V., and Garland S.M. Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J Clin Microbiol 44 9 (2006) 3213-3217
27. Reed B.D., Gorenflo D.W., Gillespie B.W., et al. Sexual behaviors and other risk factors for Candida vulvovaginitis. J Womens Health Gend Based Med 9 (2000) 645-655
28. Ohmit S.E., Sobel J.D., Schuman P., et al. A longitudinal study of mucosal Candida colonization and candidiasis among HIV-seropositive and at-risk HIV-seronegative women. J Infect Dis 188 (2003) 118-127
29. Hooten T.M., Roberts P.L., and Stamm W.E. Effect of recent sexual activity and use of diaphragm on vaginal flora. Clin Infect Dis 19 (1994) 274-278
30. Barbone F., Austin H., Louv W.C., et al. A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis. Am J Obstet Gynecol 163 (1990) 510-514
31. Spinillo A., Capuzzo E., Egbe T.O., et al. Torulopsis glabrata vaginitis. Obstet Gynecol 85 (1995) 993-998
32. Giraldo P., von Nowaskonski A., Gomes F.A., et al. Vaginal colonization by Candida in asymptomatic women with and without a history of recurrent vulvovaginal candidiasis. Obstet Gynecol 95 (2000) 413-416
33. Chaim W., Foxman B., and Sobel J.D. Association of recurrent vaginal candidiasis and secretory ABO and Lewis phenotype. J Infect Dis 176 (1997) 828-830
34. Giraldo P.C., Babula O., Gonçalves A.K., et al. Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol 109 5 (2007) 1123-1128
35. Fidel Jr. P.L., Barousse M., Espinosa T., et al. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun 72 5 (2004) 2939-2946
36. Barousse M.M., Steele C., Dunlap K., et al. Growth inhibition of Candida albicans by human vaginal epithelial cells. J Infect Dis 184 (2001) 1489-1493
37. Eckert L.O., Hawes S.E., Stevens C.E., et al. Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol 92 (1998) 757-765
38. Bergman J.J., Berg A.O., Schneeweis R., et al. Clinical comparison of microscopic and culture techniques in the diagnosis of Candida vaginitis. J Fam Pract 18 (1984) 549-552
39. Nurbhai M., Grimshaw J., Watson M., et al. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev 4 (2007 Oct 17) CD002845
40. Seidman L.S., and Skokos C.K. An evaluation of butoconazole nitrate 2% site release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to relief of symptoms in patients with vulvovaginal candidiasis. Infect Dis Obstet Gynecol 13 4 (2005) 197-206
41. Sobel J.D., Brooker D., Stein G.E., et al. Single oral dose fluconazole compared with conventional topical therapy of Candida vaginitis. Am J Obstet Gynecol 172 (1995) 1263-1268
42. Sobel J.D. Recurrent vulvovaginal candidiasis: a prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med 315 (1986) 1455-1458
43. Davidon F., and Mould R.F. Recurrent genital candidosis in women and the effect of intermittent prophylactic treatment. Br J Vener Dis 54 (1978) 176-183
44. Fong I.W. The value of treating the sexual partners of women with recurrent vaginal candidiasis with ketoconazole. Genitourin Med 68 (1992) 174-176
45. Dennerstein G.J. Depo-Provera in the treatment of recurrent vulvovaginal candidiasis. J Reprod Med 31 (1986) 801-803
46. Hilton E., Isenberg H.D., Alperstein P., et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 116 5 (1992) 353-357
47. Pirotta M., Gunn J., Chondros P., et al. Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomised controlled trial. BMJ 329 7465 (2004) 548
48. Rigg D., Miller M.M., and Metzger W.J. Recurrent allergic vulvovaginitis; treatment with Candida albicans allergen immunotherapy. Am J Obstet Gynecol 162 (1990) 332-336
49. Sood G., Nyirjesy P., Weitz M.V., et al. Terconazole cream for non-Candida albicans fungal vaginitis: results of a retrospective analysis. Infect Dis Obstet Gynecol 8 (2000) 240-243
50. Sobel J.D., Chaim W., Nagappan V., et al. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 189 5 (2003) 1297-1300
51. Horowitz B. Topical flucytosine for chronic recurrent Candida tropicalis infections. J Reprod Med 31 (1986) 821-824
52. Phillips A.J. Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories. Am J Obstet Gynecol 192 6 (2005) 2009-2012
53. White D.J., Habib A.R., Vanthuyne A., et al. Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections. Sex Transm Infect 77 3 (2001) 212-213
54. Allsworth J.E., and Peipert J.F. Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Obstet Gynecol 109 1 (2007) 114-120
55. Marazzo J.M., Koutsky L.A., Eschenbach D.A., et al. Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J Infect Dis 185 (2002) 1307-1313
56. American College of Obstetricians and Gynecologists. Vaginitis. ACOG Practice Bulletin No. 72. Obstet Gynecol 107 (2006) 1195-1206
57. Beigi R.H., Austin M.N., Meyn L.A., et al. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol 191 (2004) 1124-1129
58. Koumans E.H., Kendrick J.S., and CDC Bacterial Vaginosis Working Group. Preventing adverse sequelae of bacterial vaginosis: a public health program and research agenda. Sex Transm Dis 28 (2001) 292-297
59. Torok M.R., Miller W.C., Hobbs M.M., et al. The association between Trichomonas vaginalis infection and level of vaginal lactobacilli, in nonpregnant women. J Infect Dis 196 7 (2007) 1102-1107
60. Schwebke J.R., and Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol 196 6 (2007) 517 e1-6
61. Schwebke J.R., and Weiss H.L. Interrelationships of bacterial vaginosis and cervical inflammation. Sex Transm Dis 29 (2002) 59-64
62. Goldenberg R.L., Culhane J.F., Iams J.D., et al. Epidemiology and causes of preterm birth. Lancet 371 9606 (2008) 75-84
63. Nugent R.P., Krohn M.A., and Hillier S.L. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol 29 (1991) 297-301
64. Landers D.V., Wiesenfeld H.C., Heine R.P., et al. Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol 190 (2004) 1004-1010
65. Schwebke J.R., Richey C.M., and Weiss H.L. Correlation of behaviors with microbiologic changes in vaginal flora. J Infect Dis 180 (1999) 1632-1636
66. Gardner H.L., and Dukes C.D. Haemophilus vaginalis vaginitis: a newly defined specific infection previously classified non-specific vaginitis. Am J Obstet Gynecol 69 5 (1955) 962-976
67. Ness R.B., Hillier S.L., Richter H.E., et al. Douching in relation to bacterial vaginosis, lactobacilli, and facultative bacteria in the vagina. Obstet Gynecol 100 (2002) 765-772
68. Fredricks D.N., Fiedler T.L., Thomas K.K., et al. Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol 45 10 (2007) 3270-3276
69. Kalra A., Palcu C.T., Sobel J.D., et al. Bacterial vaginosis: culture- and PCR-based characterizations of a complex polymicrobial disease's pathobiology. Curr Infect Dis Rep 9 6 (2007) 485-500
70. Hauth J.C., MacPherson C., Carey C., et al. Early pregnancy threshold vaginal pH and gram stain scores predictive of subsequent preterm birth in asymptomatic women. Am J Obstet Gynecol 188 (2003) 831-835
71. Pereira L., Culhane J., McCollum K., et al. Variation in microbiologic profiles among pregnant women with bacterial vaginosis. Am J Obstet Gynecol 193 (2005) 746-751
72. Culhane J.F., Nyirjesy P., McCollum K., et al. Variation in vaginal immune parameters and microbial hydrolytic enzymes in bacterial vaginosis positive pregnant women with and without mobiluncus species. Am J Obstet Gynecol 195 (2006) 516-521
73. Paavonen J., Mangioni C., Martin M.A., et al. Vaginal clindamycin and oral metronidazole for bacterial vaginosis: a randomized trial. Obstet Gynecol 96 (2000) 256-260
74. Livengood III C.H., Ferris D.G., Wiesenfeld H.C., et al. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol 110 (2007) 302-309
75. Nyirjesy P., McIntosh M.J., Steinmetz J.I., et al. The effects of intravaginal clindamycin and metronidazole therapy on vaginal mobiluncus morphotypes in patients with bacterial vaginosis. Sex Transm Dis 34 (2007) 197-202
76. Diav-Citrin O., Shechtman S., Gotteiner T., et al. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology 63 (2001) 186-192
77. Iams J.D., Romero R., Culhane J.F., et al. Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth. Lancet 371 9607 (2008) 164-175
78. Wilson J. Managing recurrent bacterial vaginosis. Sex Transm Infect 80 (2004) 8-11
79. Bradshaw C.S., Morton A.N., Hocking J., et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 193 11 (2006) 1478-1486
80. Bradshaw C.S., Tabrizi S.N., Fairley C.K., et al. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J Infect Dis 194 6 (2006) 828-836
81. Sanchez S., Garcia P.J., Thomas K.K., et al. Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol 191 6 (2004) 1898-1906
82. Sobel J.D., Ferris D., Schwebke J., et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 194 (2006) 1283-1289